Doxycycline for the prevention of tick-borne relapsing fever [1]

New England Journal of Medicine

Volumn 355, Issue 15, 2006, Pages 1614-

  Croft, Ashley M ^a   Jackson, Christopher J ^b   Darbyshire, Alicia H ^b  

^a Headquarters Fifth Division   (United Kingdom)

^b Camp Souter ^*  (Afghanistan)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE;

BORRELIA INFECTION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HEALTH SURVEY; HUMAN; INFECTION PREVENTION; LETTER; NAUSEA; PRIORITY JOURNAL; RASH; TICK; TICK BORNE DISEASE; VAGINAL PRURITUS; VOMITING;

ANTI-BACTERIAL AGENTS; ANTIMALARIALS; DOXYCYCLINE; HUMANS; MALE; RELAPSING FEVER;

EID: 33749635409     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc062175     Document Type: Letter

References (5)

1. Hasin T, Davidovitch N, Cohen R, et al. Postexposure treatment with doxycycline for the prevention of tick-borne relapsing fever. N Engl J Med 2006;355:148-55.
2. Phillips MA, Kass RB. User acceptability patterns for mefloquine and doxycycline malaria chemoprophylaxis. J Travel Med 1996;3:40-5.
3. Passier A, Smits-van Herwaarden A, van Puijenbroek E. Photoonycholysis associated with the use of doxycycline. BMJ 2004;329:265.
4. Croft AM, Whitehouse DP, Cook GC, Beer MD. Safety evaluation of the drugs available to prevent malaria. Expert Opin Drug Saf 2002;1:19-27.
5. Evans SR, Korch GW Jr, Lawson MA. Comparative field evaluation of permethrin and deet-treated military uniforms for personal protection against ticks (Acari). J Med Entomol 1990;27:829-34.